Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

11.4K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.4K
Amyloid Fibrils03:03

Amyloid Fibrils

6.2K
6.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

648
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
648

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromatography-Free Analysis of Mixtures Using a Two-Dimensional Mass Spectrometry (2DMS)-Enabled Quadrupole Time-of-Flight (QToF) Analyzer.

Analytical chemistry·2026
Same author

Cyclic Peptide-Polymer Conjugate Characterization Using 193 nm Ultraviolet Photodissociation Tandem Mass Spectrometry.

Analytical chemistry·2026
Same author

Comparison of CID and UVPD Activation to Achieve the Structural Characterization of Some Pyrolysis Bio-Oil Components.

Rapid communications in mass spectrometry : RCM·2025
Same author

Hyphenation of Trapped Ion Mobility to Two-Dimensional Mass Spectrometry for Protein Analysis in Complex Biomixtures.

Journal of the American Society for Mass Spectrometry·2025
Same author

Cell-based high-throughput screening using a target-NanoLuc fusion construct to identify molecular glue degraders of c-Myc oncoprotein.

RSC chemical biology·2025
Same author

Fluorescent protein tags for human tropomyosin isoform comparison.

Biology open·2025

Related Experiment Video

Updated: Dec 13, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.3K

Does deamidation affect inhibitory mechanisms towards amyloid protein aggregation?

Yuko P Y Lam1, Cookson K C Chiu1, Christopher A Wootton1

  • 1Department of Chemistry, University of Warwick, Coventry, UK. p.oconnor@warwick.ac.uk.

Chemical Communications (Cambridge, England)
|August 5, 2020
PubMed
Summary

Deamidation of amyloid proteins significantly impacts site-specific inhibitors but not non-site specific inhibitors, affecting fibril formation. This research explores how protein modifications influence therapeutic strategies against amyloid aggregation.

More Related Videos

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.7K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.6K

Related Experiment Videos

Last Updated: Dec 13, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.3K
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.7K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.6K

Area of Science:

  • Biochemistry
  • Protein Chemistry
  • Drug Discovery

Background:

  • Deamidated amyloid proteins accelerate fibril formation.
  • Amyloid aggregation is implicated in various neurodegenerative diseases.
  • Understanding protein modifications is crucial for developing effective inhibitors.

Purpose of the Study:

  • To investigate the influence of amyloid protein deamidation on inhibitor performance.
  • To determine how deamidation affects the interaction site between inhibitors and amyloid proteins.
  • To compare the impact of deamidation on site-specific versus non-site specific inhibitors.

Main Methods:

  • In vitro studies of amyloid protein deamidation.
  • Analysis of inhibitor-amyloid protein interactions.
  • Comparative assessment of inhibition mechanisms.

Main Results:

  • Deamidation significantly influences the inhibition performance of site-specific inhibitors.
  • The interaction site between site-specific inhibitors and amyloid proteins is affected by deamidation.
  • Deamidation of amyloid proteins does not significantly disrupt the inhibition mechanism of non-site specific inhibitors.

Conclusions:

  • Amyloid protein deamidation is a critical factor to consider when designing site-specific inhibitors.
  • Non-site specific inhibitors may offer a more robust therapeutic approach against deamidated amyloid species.
  • These findings have implications for the development of treatments for amyloid-related diseases.